About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Prognostic Impact of PMI in Stable CAD Undergoing PCI

NCT04239404·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Zhangwei Chen, MD
CONTACT
+86 21 64041990 chen.zhangwei@zs-hospital.sh.cn
Danbo Lu, PhD
CONTACT
+86 21 64041990 lu.danbo@zs-hospital.sh.cn

Lead

Shanghai Zhongshan Hospital

Age

18–85

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

underwent elective coronary stenting
patients permit informed consents

You may not be if

acute STEMI
NYHA class III-IV heart failure
moderate-to-severe valvular disease
missing post-PCI troponin results
active infection, respiratory failure
liver dysfunction (liver enzyme \>3xURL or bilirubin \>2xURL),
malignancy and systemic connective tissue disease
unable to get a informed consents

The record

StatusUnknown

PhaseNo phase

Taking part2,000

StartedJan 2017

UpdatedJan 27, 2020

Conditions

Periprocedural Myocardial Injury Coronary Artery Disease Percutaneous Coronary Intervention

Where1

180 Fenglin Road
Shanghai, Shanghai Municipality, China